Sonoma Pharmaceuticals (FRA:O8Z) Institutional Ownership: 0.68% (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O8Z Sonoma Pharmaceuticals Inc FRA:O8Z
45 GF Score
Price €2.72
GF Value €3.21
! 3 Warning Signs
View Full Analysis

What is Sonoma Pharmaceuticals Institutional Ownership?

Sonoma Pharmaceuticals FRA:O8Z 45 Institutional Ownership is 0.68% as of Aug. 24, 2026. GuruFocus rates FRA:O8Z with a GF Score™ of 45/100 and a GF Value™ of €3.21. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sonoma Pharmaceuticals's institutional ownership is 0.68%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sonoma Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sonoma Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.89%.

Sonoma Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Sonoma Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonoma Pharmaceuticals Institutional Ownership Chart

Sonoma Pharmaceuticals Historical Data

The historical data trend for Sonoma Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 1.56 1.56 0.94 0.94 0.94 1.16 0.58 0.58 0.68 0.68
FRA:O8Z
45GF Score
Sonoma Pharmaceuticals Inc FRA:O8Z
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonoma Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.68% mean?
Sonoma Pharmaceuticals (FRA:O8Z) has a Institutional Ownership of 0.68% as of Aug. 24, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sonoma Pharmaceuticals and its competitors.
Is Sonoma Pharmaceuticals' Institutional Ownership too high?
Sonoma Pharmaceuticals' current Institutional Ownership is 0.68%. Overall, Sonoma Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Institutional Ownership compare to YCBD and CVSI?
Sonoma Pharmaceuticals' Institutional Ownership of 0.68% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sonoma Pharmaceuticals and its competitors. Sonoma Pharmaceuticals's current Institutional Ownership is 0.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Institutional Ownership of 0.68%. The stock's GF Value™ is €3.21, compared to a current price of €2.72 — trading 15.3% below its estimated fair value. The current Institutional Ownership is 0.68%. Sonoma Pharmaceuticals' overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Institutional Ownership is 0.68% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?

Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued. The current stock price of €2.72 is trading 15.3% below its estimated GF Value™ of €3.21.

Key valuation signals for FRA:O8Z:

  • Institutional Ownership: 0.68%
  • GF Value™: €3.21 vs. price of €2.72 (15.3% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonoma Pharmaceuticals Business Description

Other Exchanges SNOA:USA
Address 5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
45GF Score

Get the complete analysis for FRA:O8Z

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€3.21
GF Value